OUR PIPELINE

our pipeline - type texture hero

A new standard in radiation oncology

Through our lead product NBTXR3, we aim to help millions of patients fighting cancer worldwide by improving treatment outcomes without increasing harmful side effects. We believe that radiotherapy-activated NBTXR3 has the potential to become the global standard of care in the treatment of solid tumors.

NBTXR3 in the clinic

Patients (Current Study)
N
Phase I
Phase II
Phase III
Operational Sponsor
Milestone
Head & Neck
Elderly Cisplatin-ineligible (NANORAY-312, RT-R3 +/- cetuximab vs RT +/- cetuximab)
500
Nanobiotix
Janssen*
Last Patient Recruited 1H26
R/M IO Naïve (Study 1100, RT-R3 fb anti-PD-1)
35+
Nanobiotix
New Data 1H24
R/M IO Resistant (Study 1100, RT-R3 fb anti-PD-1)
35+
Nanobiotix
New Data 1H24
R/M (MDA-0541, RT-R3 fb anti-PD-1)
60
MD Anderson Cancer Center
Lung
Inoperable, Stage 3
NA
Janssen
First Patient Randomized
Inoperable, Recurrent (MDA-0123, Reirradiation RT-R3)
24
MD Anderson Cancer Center
First Data 1H25
Expansion Opportunities
Soft Tissue Sarcoma (Act.In.Sarc, RT-R3 fb resection)
180
Nanobiotix
Completed
Rectal (Study 1001, RT-R3 concurrent CT)
32
Nanobiotix
Completed
Advanced Solid (MDA-0618, RT-R3 with anti-PD-1)
40
MD Anderson Cancer Center
Cisplatin-eligible H&N (Study 1002, RT-R3 concurrent CT)
12
Nanobiotix
Completed
HCC & Liver Mets (Study 103, RT-R3)
23
Nanobiotix
Completed
Pancreas (MDA-1001, RT-R3)
24
MD Anderson Cancer Center
Updated Data 2H24
Esophageal (MDA-0122, RT-R3 concurrent CT)
24
MD Anderson Cancer Center
First Data FY25
IO Resistant Multiple Primary Tumors (Study 1100, RT-R3 fb anti-PD-1)
35+
Nanobiotix
First Data FY25

Nanobiotix granted Janssen a worldwide license for the development and commercialization of NBTXR3 as announced July 10, 2023; On December 26, 2023, Nanobiotix announced that Janssen had assumed responsibility for operations in Asia after securing global rights to NBTXR3 in China and Other Asian markets from former Nanobiotix collaborator LianBio; Nanobiotix and Janssen have also aligned to intent to transfer the global sponsorship for NANORAY-312 as announced on May 21, 2024; IO Resistant Mets: Metastases from different primary tumors in IO resistant patients; RT-R3: RT activated NBTXR3; fb: followed by; CT: chemotherapy.

Clinical trials

Radiotherapy-activated NBTXR3 is currently being evaluated alone and in combination with other anticancer therapies in ongoing clinical trials that span an array of solid tumors. These trials evaluate the efficacy and safety of NBTXR3 in various cancer types and will provide important insights into the potential applications of it in clinical practice.

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.